000 01622 a2200469 4500
005 20250514181443.0
264 0 _c20040416
008 200404s 0 0 eng d
022 _a0022-3417
024 7 _a10.1002/path.1521
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSieben, Nathalie L G
245 0 0 _aIn ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
_h[electronic resource]
260 _bThe Journal of pathology
_cMar 2004
300 _a336-40 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aCystadenoma, Mucinous
_xgenetics
650 0 4 _aCystadenoma, Papillary
_xgenetics
650 0 4 _aCystadenoma, Serous
_xgenetics
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMutation
650 0 4 _aOvarian Neoplasms
_xgenetics
650 0 4 _aProto-Oncogene Proteins
_xgenetics
650 0 4 _aProto-Oncogene Proteins B-raf
650 0 4 _aProto-Oncogene Proteins c-raf
_xgenetics
650 0 4 _aProto-Oncogene Proteins p21(ras)
650 0 4 _aras Proteins
700 1 _aMacropoulos, Patricia
700 1 _aRoemen, Guido M J M
700 1 _aKolkman-Uljee, Sandra M
700 1 _aJan Fleuren, Gert
700 1 _aHoumadi, Rifat
700 1 _aDiss, Tim
700 1 _aWarren, Bretta
700 1 _aAl Adnani, Mudher
700 1 _aDe Goeij, Anton P M
700 1 _aKrausz, Thomas
700 1 _aFlanagan, Adrienne M
773 0 _tThe Journal of pathology
_gvol. 202
_gno. 3
_gp. 336-40
856 4 0 _uhttps://doi.org/10.1002/path.1521
_zAvailable from publisher's website
999 _c14712584
_d14712584